# Omeza

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omeza

- Industry: Healthcare
- Headquarters: Sarasota, US
- Website: www.omeza.com/
- Total disclosed funding: $8.5M
- Latest round: Series A (Apr 21, 2026)
- Investors on record: 4

## About

Omeza LLC, based in the US, specializes in advanced wound care solutions, offering innovative products designed specifically to enhance healing processes for patients with chronic wounds and serious skin conditions.Omeza LLC, founded in 2014 in Sarasota, US, focuses on advanced wound care technology. It was formed to address complex wound healing challenges and has made strategic advancements to its product offerings. The company recently completed its Series A funding round, raising USD 8.5 mn on April 21, 2026, with participation from Astanor Ventures, BluKap, Catalyst Investments, and Florida Opportunity Fund. The founder’s background is not specified, and there is no mention of previous companies founded by them.Omeza specializes in advanced wound care solutions, primarily through its proprietary product, the OCM™ wound matrix. This innovative drug-device combination is designed to facilitate comprehensive healing across all phases of wound recovery, particularly focusing on chronic wounds that often resist standard treatment methods. The OCM™ technology provides personalized therapy administered by healthcare professionals, effectively addressing the unique challenges faced by patients with serious skin conditions. The primary customer base includes healthcare providers, such as hospitals and clinics, along with patients suffering from various skin issues. Omeza’s products are marketed primarily in the United States, aiming to enhance skin integrity and optimize skin quality for both individuals with severe skin problems and the broader population seeking effective wound care solutions.Omeza generates its revenue through the sale of its flagship product, OCM™, primarily via healthcare institutions and clinics that utilize this advanced wound care technology in patient treatment protocols. The business model is structured around direct transactions with healthcare providers, ensuring that the product reaches end-users effectively. Pricing plans for the OCM™ wound matrix are set to align with the medical sector’s pricing standards, allowing for straightforward procurement by hospitals and clinics. The company focuses on establishing partnerships with healthcare providers to integrate its product into existing treatment regimens, thus facilitating a seamless transaction experience. By positioning itself within the healthcare industry, Omeza reinforces its commitment to delivering comprehensive wound care solutions that address critical patient needs.In April 2026, Omeza LLC raised USD 8.5 mn in Series A funding to accelerate clinical trials, expand commercial capabilities, and strengthen its clinical and real-world evidence base to support broader reimbursement coverage. The company plans to launch new product enhancements and expand into additional geographic regions, although specific target markets and launch dates have yet to be detailed. The recent funding will directly support these initiatives, enabling Omeza to further its mission in the wound care space.

## Funding rounds

- Series A, Apr 21, 2026, $8.5M — Catalyst Investments, Florida Opportunity Fund, Astanor Ventures, BluKap

## Investors

- Catalyst Investments (https://capitalatlas.ai/funds/catalyst-investments) — Series A
- Florida Opportunity Fund (https://capitalatlas.ai/funds/florida-opportunity-fund) — Series A
- Astanor Ventures (https://capitalatlas.ai/funds/astanor-ventures) — Series A
- BluKap (https://capitalatlas.ai/funds/blukap) — Series A